KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Repurchased
Ratios

GoodRx Holdings (GDRX) Depreciation & Amortization (IS) (2019 - 2025)

Historic Depreciation & Amortization (IS) for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $21.4 million.

  • GoodRx Holdings' Depreciation & Amortization (IS) rose 2221.84% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 1369.7%. This contributed to the annual value of $69.5 million for FY2024, which is 3541.44% down from last year.
  • Latest data reveals that GoodRx Holdings reported Depreciation & Amortization (IS) of $21.4 million as of Q3 2025, which was up 2221.84% from $19.7 million recorded in Q2 2025.
  • Over the past 5 years, GoodRx Holdings' Depreciation & Amortization (IS) peaked at $43.6 million during Q4 2023, and registered a low of $5.4 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (IS) was $15.9 million (2024), whereas its average is $17.3 million.
  • As far as peak fluctuations go, GoodRx Holdings' Depreciation & Amortization (IS) soared by 18074.42% in 2023, and later crashed by 5620.99% in 2024.
  • Over the past 5 years, GoodRx Holdings' Depreciation & Amortization (IS) (Quarter) stood at $10.6 million in 2021, then surged by 45.88% to $15.5 million in 2022, then surged by 180.74% to $43.6 million in 2023, then crashed by 56.21% to $19.1 million in 2024, then rose by 12.23% to $21.4 million in 2025.
  • Its last three reported values are $21.4 million in Q3 2025, $19.7 million for Q2 2025, and $20.9 million during Q1 2025.